Figure 3
Forest plot showing the incidence of major adverse cardiovascular events (MACE) with SGLT-2 inhibitors compared with placebo in patients with and without chronic kidney disease (CKD). Results are stratified by CKD status. Data are presented as risk ratios (RR) with 95% confidence intervals (95% CI). A lower incidence of MACE is identified with SGLT-2 inhibitors compared with placebo in patients with and without CKD (p for interaction 0.44). A random effects model is used. Definition of MACE is detailed in Table 1.
